FORTEO® (teriparatide [rDNA origin] 20 mcg for injection)

Brief Summary. Consult the package insert for complete prescribing information.

WARNING: POTENTIAL RISK OF OSTEOSARCOMA

In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide ranging from 3 to 60 times the exposure in humans given a 20-mcg dose. Because of the uncertain relevance of the rat osteosarcoma finding to humans, prescribe FORTEO with caution for patients for whom the potential benefits are considered to outweigh the potential risk. FORTEO should not be prescribed for patients who are at increased baseline risk for osteosarcoma (including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).

INDICATIONS

FORTEO is indicated: for the treatment of postmenopausal women with osteoporosis at high risk for fracture; to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture; for the treatment of men and women with osteoporosis associated with sustained, systemic glucocorticoid therapy at high risk for fracture.

CONTRAINDICATIONS

Do not use FORTEO in patients with Hypersensitivity to teriparatide or to any of its excipients. Reactions have included angioedema and anaphylaxis.

WARNINGS AND PRECAUTIONS

Osteosarcoma In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. FORTEO should not be prescribed for patients at increased baseline risk of osteosarcoma. These include Paget's disease of bone (unexplained elevations of alkaline phosphatase may indicate Paget's disease of bone); pediatric and young adult patients with open epiphyses; prior external beam or implant radiation therapy involving the skeleton. Patients should be encouraged to enroll in the Patient Registry, which is designed to collect information about any potential risk of osteosarcoma in patients who have taken FORTEO. Enrollment information can be obtained by calling 1-866-382-6813, or by visiting www.forteregistry.org.

Treatment Duration The safety and efficacy of FORTEO have not been evaluated beyond 2 years of treatment. Consequently, use of the drug for more than 2 years during a patient's lifetime is not recommended.

Bone Metastases and Skeletal Malignancies Patients with bone metastases or a history of skeletal malignancies should not be treated with FORTEO. Metabolic Bone Diseases Patients with metabolic bone diseases other than osteoporosis should not be treated with FORTEO. Hyperparathyroidism and Hypercalcemia Disorders FORTEO has not been studied in patients with pre-existing hypercalcemia. These patients should not be treated with FORTEO because of the possibility of exacerbating hypercalcemia. Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with FORTEO. Urolithiasis or Pre-existing Hypercalcemia In clinical trials, the frequency of urolithiasis was similar in patients treated with FORTEO and placebo. However, FORTEO has not been studied in patients with active urolithiasis. If active urolithiasis or pre-existing hypercalcemia are suspected, measurement of urinary calcium excretion should be considered. FORTEO should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition.

Orthostatic Hypotension Hypotension should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur. In short-term clinical pharmacology studies with teriparatide, transient episodes of symptomatic orthostatic hypotension were observed in 5% of patients. Typically, an event began within 4 hours of dosing and spontaneously resolved within a few minutes to a few hours. When transient orthostatic hypotension occurred, it happened within the first several doses, it was relieved by placing the person in a reclining position, and it did not preclude continued treatment.

Drug Interactions Hypercalcemia may predispose patients to digitalis toxicity. Because FORTEO transiently increases serum calcium, patients receiving digoxin should use FORTEO with caution.

ADVERSE REACTIONS

Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Treatment of Osteoporosis in Men and Postmenopausal Women The safety of FORTEO in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years). The median durations of the trials were 11 months for men and 13 months for women, with 691 patients exposed to FORTEO and 691 patients to placebo. All patients received 1000 mg of calcium plus at least 400 IU of vitamin D supplementation per day. The incidence of all cause mortality was 1% in the FORTEO group and 1% in the placebo group. The incidence of serious adverse events was 16% in FORTEO patients and 19% in placebo patients. Early discontinuation due to adverse events occurred in 7% of FORTEO patients and 6% of placebo patients. Percentage of Patients with Adverse Events Reported by at Least 2% of FORTEO-Treated Patients and in More FORTEO-Treated Patients than Placebo-Treated Patients from the Two Principal Osteoporosis Trials in Men and Women Adverse Events Are Shown Without Attribution of Causality (FORTEO, N=691, Placebo, N=691):

Body as a Whole: Rash (4.9%, 4.5%), Sweating (2.2%, 1.7%). Immunogenicity In the clinical trials, antibodies that cross-reacted with teriparatide were detected in 3% of women (15/541) receiving FORTEO. Enrollment information can be obtained by calling 1-866-382-6813, or by visiting www.forteregistry.org.

Managed Care Considerations

CPT Code: 29882

Description: Arthroscopy, knee, surgical, with meniscus repair (medial or lateral)

Units: 1

CPT Code: 29889

Description: Arthroscopy, knee surgical, for removal of loose body, foreign body, debridement/shaving of articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee

TABLE 2: REPORTING WITH BUNDLED OPTION

<table>
<thead>
<tr>
<th>CPT Code/ Modifier(s)</th>
<th>Description</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>29882</td>
<td>Arthroscopy, knee, surgical, with meniscus repair (medial or lateral)</td>
<td>1</td>
</tr>
<tr>
<td>29889</td>
<td>Arthroscopy, knee surgical, for removal of loose body, foreign body, debridement/shaving of articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee</td>
<td>2</td>
</tr>
</tbody>
</table>

ADVERSE REACTIONS

Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Treatment of Osteoporosis in Men and Postmenopausal Women The safety of FORTEO in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years). The median durations of the trials were 11 months for men and 13 months for women, with 691 patients exposed to FORTEO and 691 patients to placebo. All patients received 1000 mg of calcium plus at least 400 IU of vitamin D supplementation per day. The incidence of all cause mortality was 1% in the FORTEO group and 1% in the placebo group. The incidence of serious adverse events was 16% in FORTEO patients and 19% in placebo patients. Early discontinuation due to adverse events occurred in 7% of FORTEO patients and 6% of placebo patients. Percentage of Patients with Adverse Events Reported by at Least 2% of FORTEO-Treated Patients and in More FORTEO-Treated Patients than Placebo-Treated Patients from the Two Principal Osteoporosis Trials in Men and Women Adverse Events Are Shown Without Attribution of Causality (FORTEO, N=691, Placebo, N=691):

Body as a Whole: Rash (4.9%, 4.5%), Sweating (2.2%, 1.7%). Immunogenicity In the clinical trials, antibodies that cross-reacted with teriparatide were detected in 3% of women (15/541) receiving FORTEO. Enrollment information can be obtained by calling 1-866-382-6813, or by visiting www.forteregistry.org.

Managed Care Considerations

CPT Code: 29882

Description: Arthroscopy, knee, surgical, with meniscus repair (medial or lateral)

Units: 1

CPT Code: 29889

Description: Arthroscopy, knee surgical, for removal of loose body, foreign body, debridement/shaving of articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee

TABLE 2: REPORTING WITH BUNDLED OPTION

<table>
<thead>
<tr>
<th>CPT Code/ Modifier(s)</th>
<th>Description</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>29882</td>
<td>Arthroscopy, knee, surgical, with meniscus repair (medial or lateral)</td>
<td>1</td>
</tr>
<tr>
<td>29889</td>
<td>Arthroscopy, knee surgical, for removal of loose body, foreign body, debridement/shaving of articular cartilage (chondroplasty) at the time of other surgical knee arthroscopy in a different compartment of the same knee</td>
<td>2</td>
</tr>
</tbody>
</table>